+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Syncytial Virus Vaccine for the Elderly Market - Global Forecast 2026-2032- Product Image
Respiratory Syncytial Virus Vaccine for the Elderly Market - Global Forecast 2026-2032- Product Image
Sale

Respiratory Syncytial Virus Vaccine for the Elderly Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6081818
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Syncytial Virus Vaccine for the Elderly Market is projected to reach USD 1.96 Billion in 2026. It is expected to continue growing at a CAGR of 5.33%, reaching USD 2.67 Billion by 2032.

RSV Vaccination for Older Adults: Executive Overview

Respiratory syncytial virus (RSV) can cause severe lower-respiratory illness in older adults, particularly those with chronic heart or lung disease, weakened immunity, frailty, or residence in congregate settings. The introduction of vaccines for older populations has added an important prevention option alongside clinical surveillance, infection-control measures, and timely diagnosis. Policy and clinical priorities differ by age threshold, risk profile, seasonality, product authorization, and national immunization guidance.

How RSV Prevention Is Reshaping Older-Adult Care

The RSV prevention landscape is shifting from primarily supportive treatment toward risk-based prevention across primary care, pharmacy, hospitals, and long-term-care systems. Key changes include greater use of shared clinical decision-making, integration with influenza and COVID-19 vaccination workflows, stronger attention to coadministration evidence, and improved identification of high-risk older adults. Implementation also depends on product safety monitoring, seasonal timing, reimbursement, provider awareness, and public confidence.

Artificial Intelligence Strengthens RSV Immunization Operations

Artificial intelligence can support RSV prevention by identifying eligible patients from electronic health records, flagging chronic conditions associated with severe disease, predicting missed vaccination opportunities, and optimizing outreach before seasonal transmission increases. It may also improve pharmacovigilance, demand planning, appointment scheduling, and analysis of respiratory-virus surveillance. These applications require validated datasets, transparent clinical oversight, privacy safeguards, bias monitoring, and clear separation between decision support and autonomous medical decisions.

Regional Differences Shape Access and Delivery

In North America, established adult immunization infrastructure and pharmacy delivery can support uptake, while fragmented coverage rules and unequal access remain practical barriers. Europe combines strong public-health surveillance with varied national recommendations, procurement models, and reimbursement pathways. Asia-Pacific spans mature vaccination systems and settings where adult immunization infrastructure is still developing, making workforce capacity and cold-chain reliability important. Latin America faces differences in financing, primary-care reach, and seasonal patterns. The Middle East is characterized by diverse health-system capacity, substantial expatriate populations, and the need for coordinated seasonal planning. Africa requires particular attention to surveillance, risk-based prioritization, primary-care integration, and reliable supply and distribution systems.

Multilateral Groups Influence Standards and Implementation

ASEAN members may benefit from coordinated surveillance, procurement dialogue, and approaches suited to varied health-system capacity. BRICS countries represent diverse epidemiological, manufacturing, regulatory, and financing conditions, making alignment difficult but potentially valuable for evidence exchange. The European Union benefits from cross-border regulatory and public-health coordination, although national recommendations and funding decisions remain important. G7 systems generally have stronger adult immunization infrastructure and data capacity, while still facing hesitancy and delivery gaps. GCC countries can leverage concentrated healthcare networks and coordinated procurement, with attention to migrant and older-adult populations. NATO members may apply established preparedness and logistics capabilities to protect vulnerable populations, while vaccination policy remains a national responsibility.

Country Context Determines RSV Vaccine Uptake

Australia has strong immunization governance but must address geographic access and seasonal planning. Brazil and Mexico need approaches that connect public-health programs with primary care and equitable access. Canada and the United States have broad adult-vaccination delivery channels, yet coverage can vary by jurisdiction, insurance, and provider recommendation. China and India face large, diverse older populations and substantial differences between urban and rural delivery capacity. Japan and South Korea have advanced healthcare systems with opportunities for coordinated geriatric and respiratory care. France, Germany, Italy, Spain, and the United Kingdom combine established health services with differing eligibility guidance, reimbursement, and primary-care workflows. Russia’s implementation context is shaped by its regulatory, procurement, surveillance, and regional healthcare structures.

Practical Priorities for Industry and Health-System Leaders

Leaders should align clinical evidence with clearly defined older-adult risk groups and communicate benefits, limitations, and safety information in plain language. Build vaccination pathways into routine primary care, pharmacies, discharge planning, and long-term-care services; coordinate RSV delivery with other seasonal immunizations where guidance permits; and use reminders targeted to clinically eligible patients. Strengthen post-authorization safety monitoring, transparent reporting, provider education, and equity audits. Partnerships with public-health agencies should focus on surveillance, cold-chain resilience, reimbursement clarity, and measurable outcomes such as recommendation rates, completed vaccinations, and severe RSV admissions avoided.

Evidence-Based Methodology for the Executive Summary

This summary uses the supplied market scope-RSV vaccination for elderly populations-and synthesizes established public-health, clinical, regulatory, and health-system considerations without presenting market estimates, shares, sizing, or forecasts. Interpretation is organized across six required regions, six multinational groups, and the specified countries. Conclusions emphasize generalizable implementation factors, including disease burden risk, eligibility policy, access, delivery infrastructure, surveillance, safety monitoring, and responsible use of artificial intelligence. Country and group observations are intentionally framed as contextual insights rather than claims of uniform national policy.

Prevention Success Depends on Trusted, Equitable Delivery

RSV vaccination can complement broader respiratory-virus prevention for older adults, but its public-health value depends on reaching people most likely to experience severe disease at the appropriate time. Effective implementation requires evidence-aligned recommendations, accessible delivery points, informed healthcare professionals, reliable safety monitoring, and sustained public confidence. Across regions and country groups, leaders should treat vaccination as part of an integrated older-adult respiratory-care strategy rather than as a standalone intervention.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Type
7.1. Introduction
7.2. Live Attenuated
7.3. mRNA
7.4. Recombinant
7.5. Subunit
8. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Route Of Administration
8.1. Introduction
8.2. Intramuscular
8.3. Intranasal
9. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Age Cohort
9.1. Introduction
9.2. 65-74 Years
9.3. 75-84 Years
9.4. 85 Years And Above
10. Respiratory Syncytial Virus Vaccine for the Elderly Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Clinics
10.4. Hospitals
11. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AstraZeneca plc
16.2. Bavarian Nordic A/S
16.3. BioNTech SE
16.4. Clover Biopharmaceuticals, Ltd.
16.5. CureVac N.V.
16.6. GlaxoSmithKline plc
16.7. Johnson & Johnson
16.8. Moderna, Inc.
16.9. Novavax, Inc.
16.10. Pfizer Inc.
16.11. Takeda Pharmaceutical Company Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Respiratory Syncytial Virus Vaccine for the Elderly Market, Years Considered for the Study
FIGURE 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market, Research Design
FIGURE 3. Global Respiratory Syncytial Virus Vaccine for the Elderly Market, Research Framework
FIGURE 4. Global Respiratory Syncytial Virus Vaccine for the Elderly Market, Data Triangulation
FIGURE 5. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2025 vs 2032 (%)
FIGURE 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2025 vs 2032 (%)
FIGURE 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Segmentation & Coverage
TABLE 2. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 3. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 4. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global mRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global mRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global mRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Subunit Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Subunit Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Subunit Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 17. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Intranasal Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Intranasal Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Intranasal Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 24. Global 65-74 Years Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global 65-74 Years Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global 65-74 Years Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global 75-84 Years Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global 75-84 Years Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global 75-84 Years Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global 85 Years And Above Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global 85 Years And Above Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global 85 Years And Above Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 34. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 44. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 60. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 62. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 63. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 64. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 65. North America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 66. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 68. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 69. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 70. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Latin America Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 72. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 74. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 75. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 76. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. Europe Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 78. Middle East Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Middle East Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 80. Middle East Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 81. Middle East Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 82. Middle East Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. Middle East Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 86. Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 87. Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 88. Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Africa Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. ASEAN Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. ASEAN Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 93. ASEAN Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 94. ASEAN Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 95. ASEAN Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. ASEAN Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 97. GCC Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. GCC Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 99. GCC Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 100. GCC Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 101. GCC Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. GCC Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. European Union Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. European Union Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 105. European Union Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 106. European Union Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 107. European Union Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. European Union Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. BRICS Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. BRICS Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 111. BRICS Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 112. BRICS Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 113. BRICS Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. BRICS Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. G7 Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. G7 Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 117. G7 Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 118. G7 Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 119. G7 Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. G7 Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. NATO Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. NATO Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 123. NATO Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 124. NATO Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 125. NATO Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 126. NATO Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. United States Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 129. United States Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 130. United States Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 131. United States Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 132. United States Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. United States Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. Canada Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 135. Canada Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 136. Canada Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 137. Canada Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 138. Canada Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. Canada Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 141. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 142. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 143. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 144. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 147. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 148. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 149. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 150. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 152. United Kingdom Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 153. United Kingdom Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 154. United Kingdom Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 155. United Kingdom Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 156. United Kingdom Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. United Kingdom Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. Germany Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 159. Germany Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 160. Germany Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 161. Germany Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 162. Germany Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. Germany Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. France Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 165. France Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 166. France Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 167. France Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 168. France Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. France Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. Russia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 171. Russia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 172. Russia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 173. Russia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 174. Russia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Russia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. Italy Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 177. Italy Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 178. Italy Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 179. Italy Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 180. Italy Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Italy Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 182. Spain Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 183. Spain Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 184. Spain Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 185. Spain Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 186. Spain Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Spain Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. China Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 189. China Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 190. China Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. China Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 192. China Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. China Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. India Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 195. India Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 196. India Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 197. India Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 198. India Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. India Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 200. Japan Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 201. Japan Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 202. Japan Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 203. Japan Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 204. Japan Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Japan Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 206. Australia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 207. Australia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 208. Australia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 209. Australia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 210. Australia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. Australia Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Market Size, 2017-2032 (USD Million)
TABLE 213. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 214. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 215. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Age Cohort, 2017-2032 (USD Million)
TABLE 216. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. Global Respiratory Syncytial Virus Vaccine for the Elderly Market Share, by Key Player, 2025
TABLE 219. Global Respiratory Syncytial Virus Vaccine for the Elderly Market, Key Experts

Companies Mentioned

  • AstraZeneca plc
  • Bavarian Nordic A/S
  • BioNTech SE
  • Clover Biopharmaceuticals, Ltd.
  • CureVac N.V.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Respiratory Syncytial Virus Vaccine for Children Market - Global Forecast 2026-2032 - Product Image

Respiratory Syncytial Virus Vaccine for Children Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Respiratory Syncytial Virus Vaccine Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Respiratory Syncytial Virus Vaccine Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Respiratory Syncytial Virus Vaccine Global Market Opportunities and Strategies to 2035 - Product Image

Respiratory Syncytial Virus Vaccine Global Market Opportunities and Strategies to 2035

  • Report
  • 296 Pages
  • Global
From
Respiratory Syncytial Virus Therapeutic Drugs Market - Global Forecast 2026-2032 - Product Image

Respiratory Syncytial Virus Therapeutic Drugs Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2026 - Product Image

Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2026

  • Clinical Trials
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.